Based on the aggregated intelligence of 165,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, molecular diagnostic specialist Myriad Genetics (Nasdaq: MYGN) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Myriad's business and see what CAPS investors are saying about the stock right now.

Myriad facts

Headquarters (Founded)

Salt Lake City (1991)

Market Cap

$1.5 billion

Industry

Biotechnology

Trailing-12-Month Revenue

$355 million

Management

CEO Dr. Peter Meldrum (since 1991)

CFO James Evans (since 2007)

Return on Equity (Average, Past 3 Years)

19%

Cash/Debt

$399 million / $0

Competitors

Clinical Data (Nasdaq: CLDA)

Laboratory Corp. of America (NYSE: LH)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS.

On CAPS, 89% of the 649 members who have rated Myriad believe the stock will outperform the S&P 500 going forward. These bulls include my fellow Foolish writer Anders Bylund (TMFZahrim) and UltraLong, both of whom are ranked in the top 10% of our community.

Two months ago Anders compared Myriad to another medical marvel:

Like fellow medical pioneer [Intuitive Surgical], Myriad doesn't have any real competition -- and won't until its framework of protective patents expire or get struck down. Worst case scenario, that will take years. Myriad will be back.

In early May, Myriad's stock plunged 23% after its quarterly results and full-year outlook fell well short of expectations. Since then, Myriad has fallen another 19% on worries, as expressed most recently by JPMorgan, that "lingering unemployment has weighed on physician office visits, and expansion from the core oncology base into a more fragmented OB/GYN market has proved challenging." In fact, Myriad's shares have woefully lagged genetic testing competitors Clinical Data and LabCorp by more than 40 percentage points over the past year.

According to CAPS All-Star UltraLong, however, it's just a matter of time before Mr. Market, or even an acquisition-hungry health giant, closes that fairly wide valuation gap:

They're growing at 14%-15% per year, they have $3.50 in cash per share with no debt, they plan to repurchase up to 100M dollars worth of shares. ... That makes for a PEG of 0.9 this year and close to 0.7 for 2011. Cheap cheap said the bird! People need Myriad's molecular diagnostic products and I don't see that trend of increasing shareholder value changing anytime soon. This is too good of a value to pass up and my feeling is another larger company out there is going to agree with that as well making Myriad a strong buyout candidate in the next 2 years.

What do you think about Myriad, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!